Active Ingredient(s): Etelcalcetide
FDA Approved: * February 7, 2017
Pharm Company: * KAI PHARMS INC
Category: Thyroid

Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session.[1][2] Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland.[1] Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.[3]&am... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Parsabiv 2.5 mg/.5ml Intravenous Injection, Solution
NDC: 55513-740
Amgen Inc
Parsabiv 5 mg/ml Intravenous Injection, Solution
NDC: 55513-741
Amgen Inc
Parsabiv 10 mg/2ml Intravenous Injection, Solution
NDC: 55513-742
Amgen Inc